University of Washington-ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2007

  1. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

    Blood, Vol. 109, Núm. 10, pp. 4168-4170

2005

  1. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

    Cancer, Vol. 104, Núm. 7, pp. 1442-1452

2002

  1. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)

    Leukemia, Vol. 16, Núm. 9, pp. 1627-1636

2000

  1. Genetic variation in ICF syndrome: Evidence for genetic heterogeneity

    Human Mutation, Vol. 16, Núm. 6, pp. 509-517